LONG TERM HBsAg REDUCTION BY A NASAL ADMINISTRATIVE THERAPEUTIC VACCINE CONTAINING HBsAg AND HBCAG MIXED WITH MUCOADHESIVE CVP IN PATIENTS WITH CHRONIC HBV INFECTION: THE RESULTS OF 48 MONTHS FOLLOW UP
<div><p><b>Background: </b>We reported the HBsAg reduction by a nasal administrative therapeutic vaccine containing HBsAg/HBcAg mixed with mucoadhesive excipient carboxy-vinyl polymer (CVP-NASVAC) in chronically HBV infected patients. This study was aimed to assess the long-term efficacy of CVP-NASVAC at 48 months after the first 10 doses.</p>